In the FlowLine Bipore Heparin vascular prosthesis, heparin is attached to the lumen surface of the prosthesis by means of covalent bondings and ionic interactions, a stable and permanent method.

According to the report, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval, and has a sales prediction of $1 billion.